We are live on ! Find out more
CVKD icon

Cadrenal Therapeutics
CVKD

2 hedge funds and large institutions have $429 invested in Cadrenal Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less funds holding

Funds holding: 3 → 2 (-1)

68% less capital invested

Capital invested by funds: $1.34K → $429 (-$909)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$484
2
UBS Group
UBS Group
Switzerland
-$330
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
1
Tower Research Capital (TRC)
New York
$408 -$484 -22 -55%
Wells Fargo
2
Wells Fargo
California
$15 – – –
UBS Group
3
UBS Group
Switzerland
$6 -$330 -15 Closed

CVKD Hedge Fund Activity: Q2 2023 in Review

2 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q2 2023, worth a combined $429 — down 68% from $1.34K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CVKD and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Tower Research Capital (TRC), cutting an estimated $484.

  • 2 institutional investors held Cadrenal Therapeutics (CVKD) as of Q2 2023, down from 3 in Q1 2023.
  • Funds reported $429 of Cadrenal Therapeutics stock for Q2 2023, down 68% quarter-over-quarter.
  • 0 funds opened new Cadrenal Therapeutics positions in Q2 2023 and 1 closed out, a net change of -1 holder.
  • The largest Cadrenal Therapeutics seller in Q2 2023 was Tower Research Capital (TRC), an estimated $484 sold.

Based on aggregated 13F filings for Q2 2023.